The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | Long-term follow-up of OPTIMUM/Muknine: stratified treatment for patients with high-risk myeloma
Martin Kaiser, MD, FRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, comments on the long-term follow-up of the OPTIMUM/Muknine trial (NCT03188172), which explored stratified treatment approaches for patients with high-risk multiple myeloma. Results demonstrated that 61% of patients remained progression-free at five years, and Dr Kaiser further notes that consolidation therapy is crucial for maintaining intensity in high-risk disease. The trial’s findings suggest the need for comprehensive genetic and gene expression profiling to personalize care and tailor treatment approaches for individual patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
